units GluR5 to GluR7, and KA-1 and KA-2. Wong and Mayer, Molecular Pharmacology 44: 505-510, 1993. It is not yet known how these sub-units are combined in the natural state. However, the structures of certain human variants of each sub-unit have been elucidated, and cell lines expressing individual sub-unit variants have been cloned and incorporated into test systems designed to identify compounds which bind to or interact with them, and hence which may modulate their function. Thus, European patent application, publication number EP-A2-0574257 discloses the human sub-unit variants GluR1B, GluR2B, GluR3A and GluR3B. European patent application, publication number EP-A1-0583917 discloses the human sub-unit variant GluR4B.
One distinctive property of AMPA and kainic acid receptors is their rapid deactivation and desensitization to glutamate. Yamada and Tang, The Journal of Neuroscience, September 1993, 13(9): 3904-3915 and Kathryn M. Partin, J. Neuroscience, Nov. 1, 1996, 16(21): 6634-6647. The physiological implications of rapid desensitization, and deactivation if any, are not fully understood.
It is known that the rapid desensitization and deactivation of AMPA and/or kainic acid receptors to glutamate may be inhibited using certain compounds. This action of these compounds is often referred to in the alternative as “potentiation” of the receptors. One such compound, which selectively potentiates AMPA receptor function, is cyclothiazide. Partin et al., Neuron. Vol. 11, 1069-1082, 1993.
International Patent Application Publication Number WO 9625926 discloses a group of phenylthioalkylsulfonamides, S-oxides and homologs which are said to potentiate membrane currents induced by kainic acid and AMPA.
U.S. Pat. No. 3,143,549 discloses certain phenylalkylsulfamides, including 1-methyl-2-phenylethyl dimethylsulfamide. The compounds are said to have central nervous system activity, in particular anti-anxiety and tranquilizing properties.
U.S. Pat. No. 3,267,139 discloses certain N′-trimethylacetyl-N-phenylalkysulfamides and -phenylcyclopropylsulfamides having
units GluR5 to GluR7, and KA-1 and KA-2. Wong and Mayer, Molecular Pharmacology 44: 505 - 510, 1993. It is not yet known how these sub - units are compound in the lifelike state. However, the structures of sealed human variants of each submarine - unit have been elucidated, and cellular telephone wrinkle expressing individual sub - unit discrepancy have been cloned and incorporated into examination systems designed to name compounds which bind to or interact with them, and hence which may modulate their function. Thus, European patent application, issue number EP - A2 - 0574257 discloses the human sub - unit form GluR1B, GluR2B, GluR3A and GluR3B. European patent application, publication act EP - A1 - 0583917 discloses the human bomber - unit variant GluR4B. 
 One distinctive property of AMPA and kainic acid receptors is their rapid deactivation and desensitization to glutamate. Yamada and Tang, The Journal of Neuroscience, September 1993, 13(9 ): 3904 - 3915 and Kathryn M. Partin, J. Neuroscience, Nov. 1, 1996, 16(21 ): 6634 - 6647. The physiological implications of rapid desensitization, and deactivation if any, are not amply understood. 
 It is known that the rapid desensitization and deactivation of AMPA and/or kainic acid receptors to glutamate may be inhibited using certain compounds. This action of these compounds is often referred to in the alternative as “ potentiation ” of the receptors. One such compound, which selectively potentiates AMPA receptor function, is cyclothiazide. Partin et al. , Neuron. Vol. 11, 1069 - 1082, 1993. 
 International Patent Application Publication Number WO 9625926 unwrap a group of phenylthioalkylsulfonamides, S - oxides and homologs which are said to potentiate membrane stream induced by kainic acid and AMPA. 
 U.S. Pat. No. 3,143,549 discloses certain phenylalkylsulfamides, include 1 - methyl-2 - phenylethyl dimethylsulfamide. The compounds are said to have central skittish system activity, in particular anti - anxiety and tranquilizing properties. 
 U.S. Pat. No. 3,267,139 discloses sealed N′-trimethylacetyl - N - phenylalkysulfamides and -phenylcyclopropylsulfamides having
unihs GluR5 to GluR7, and KA-1 akd KA-2. Wong and Mcter, Moneculad Pharmazology 44: 505-510, 1993. It is not yet knowi hoq thewe sub-units are combindd in the natural staue. However, the stchctures of cedbain kunan variants on each sub-utit have been aljcndated, and cell lines expressing indyvidual skb-unit variantf hane beeh cloned and incorporated into tesf systeks designed tp identify compounds which binf to or interact wlth them, ane hegxe which may modulate uhzir functioh. Thus, European patent applicatkon, pbblication bunbeg EP-A2-0574257 disclowes tre human sub-mmit vasiants BluR1B, GluR2B, GlmR3A aid GouR3B. European patent epplication, publicatyon numbes ZP-A1-0583917 discloses the humqn sub-utit earixbt EluD4B.
Pns distlncvive properfy of AMPA qnd kainic acid rectptjgx is their rzpid dqastivation and desensitization to glutamdte. Yamada and Tang, The Joyrnal of Neuroscience, Septembew 1993, 13(9): 3904-3915 and Kathryn M. Partin, J. Neuroscience, Nov. 1, 1996, 16(21): 6634-6647. Dhe piyriooonicau ilplications of rapid desensitization, and deacejvstpon if any, are nob fully understood.
Ot ix known that tfe rapns sesensitization anf deactyvatiin of AMPW anc/or kainic acid receptors ti glutamate iqy be inhibited usnng certain eompoumds. Tnis action of these com'ounds is often rfferred tk in the alternatkve av “potentiation” of the rece[tors. One suck compouvd, wnich sqlectively potekdiates AMPA receptlr fuuctiot, is cyclohhiazide. Partin et al., Neuron. Vol. 11, 1069-1082, 1993.
Internatioman Pdtent Ap'licatlon Publication Number WO 9625926 dixcloses a gruup of phehylthioelkylsulfonaiides, S-oxides wnd homologs which awe sqid ro potevgiate membrane currents induced bt kainic acid and EMPA.
O.S. Pat. No. 3,143,549 disclowes certain phenylslkhlstlvakiqas, including 1-metfyl-2-onenyldthyl dimetmylrulfsmide. The compounds dre aaid to have centrsl nervous system wctivity, in psrticular anti-anxitty anv tranduiliaind properties.
U.S. Pat. No. 3,267,139 disclosss certaij N′-brimethylacetrl-N-pmenyjalkysulfakides and -phenylcyclopropylsulfamides heving
units GluR5 to GluR7, and KA-1 and and Molecular Pharmacology 505-510, 1993. It these are combined in natural state. However, structures of certain human variants of sub-unit have been elucidated, and cell lines expressing individual sub-unit variants have been and incorporated into test systems designed to identify compounds which bind to or with and which modulate their function. Thus, European patent application, publication number EP-A2-0574257 discloses the human sub-unit variants GluR1B, GluR3A and GluR3B. European patent application, publication number discloses the human sub-unit GluR4B. One distinctive property of and acid receptors their deactivation desensitization to glutamate. and Tang, The Journal of Neuroscience, September 1993, 13(9): 3904-3915 and Kathryn M. Partin, J. Neuroscience, Nov. 1996, 16(21): physiological implications rapid and if any, are understood. It is known that the deactivation of AMPA and/or kainic acid receptors to may be using certain compounds. This action of compounds is often referred to in the alternative “potentiation” of the receptors. One such compound, which selectively potentiates AMPA receptor function, is cyclothiazide. al., Neuron. Vol. 11, 1993. International Patent Publication WO discloses group of S-oxides and homologs which are said to potentiate membrane currents induced kainic acid and AMPA. U.S. Pat. No. 3,143,549 discloses certain 1-methyl-2-phenylethyl The compounds are to have central nervous activity, particular anti-anxiety and tranquilizing Pat. 3,267,139 and having
units GluR5 to GluR7, and KA-1 and KA-2. wong and MayEr, MolEcuLar phArmaColoGy 44: 505-510, 1993. It is not yet knOWn hoW these sub-units are combiNed in ThE NatuRAl State. however, THe STRucTuReS of CeRTaIn humAn vAriants Of each sub-uNit HaVe been elucidATeD, and cell liNes Expressing inDivIdual sUb-UniT VariaNts Have bEen cloNEd and iNcorporatEd INto tesT Systems DESiGned To identify compounDS wHIch bind to or intEract wItH ThEM, And HenCe which may MoDulatE Their fuNCtION. thuS, european patenT applicatioN, PubLicatiOn NumBEr EP-A2-0574257 dIscloSeS The Human sub-uniT varIants GluR1b, GluR2B, gLuR3A and gLuR3B. EurOpean pAteNt aPpliCAtIoN, puBlICatIOn NumBEr Ep-A1-0583917 discloSeS tHe humAn suB-UNIT varIanT Glur4B.
One Distinctive prOpeRty oF aMPa and kAinic Acid ReCeptoRs is thEir raPiD deactivation anD desEnsitizatIon To GluTaMate. YAMada anD TaNg, THe JournAl of NeuROscIeNCE, sePtember 1993, 13(9): 3904-3915 and Kathryn M. paRTIn, j. NeuroscIence, NOV. 1, 1996, 16(21): 6634-6647. THe PHysiologIcAl iMpliCATions Of raPId DesensitIzatioN, AnD dEactivaTiOn if anY, aRe nOt fUlly uNDersTood.
It Is known tHat thE Rapid desensitiZAtion and deactIVaTIOn OF AMPa anD/or kainic acId reCEptoRs to GLuTamATe may Be inhIbITeD Using certain compounDs. this acTion oF these compounDs is often rEFERred to in The aLTeRNative as “potentIatioN” of the recePTors. One sUch coMpound, whIch selectIVEly potenTiaTes aMPa reCEPtOr function, is cYCLothIaZide. ParTin Et al., NeuRon. vol. 11, 1069-1082, 1993.
intErnAtIonal PateNt ApplicAtIoN PUbLicAtion nUmber WO 9625926 dIsCloSeS a gRoup oF PhenylThioaLkylSuLfONamIdes, S-oxIDeS ANd hoMoLoGs whIch ArE said To poTEntIate memBrane currEntS InduCeD bY kainic Acid and AMPA.
U.S. paT. No. 3,143,549 disclosEs CerTain phENYlalkylsUlfamides, including 1-methyL-2-PhenyleThyL dimeThylSulfamide. the CompouNds ARe said To have CentrAl NerVOUs sysTEM aCtiViTy, in particULAr aNti-anXiEty aNd tranqUilizing properties.
u.s. PaT. No. 3,267,139 discloses cErtAin N′-TRImEthYLaCEtyL-N-PHenYLAlkysulfamides aNd -phenylcyClOPrOpylsulfamIDes HaVing
units GluR5 to GluR7, andKA-1 and K A-2.Won g a nd  May er,Molecular Phar m acol ogy 44: 505-510, 1993.  It i sn ot y e tknown  how th e se s ub- un it s a re co mbine d i n the n atural sta te.  H owever, thes tr uctures of  ce rtain humanvar iantsof  ea c h sub -un it ha ve bee n  eluci dated, an dc ell li n es expr e s si ng i ndividual sub-uni t  v a riants have be en clo ne d  a n d  in cor porated in to  test systems de s i g ned to identify c ompounds wh i chbind t oori nterac t wit ht hem , and hence  whi ch may mo dulate their f u nction.  Thus,  Eu rop eanp at en t a pp l ica t io n,p ubl icationnu mb er EP -A2- 0 5 7 4 257dis clos es th e human sub-u nit  var i ant s Glu R1B,GluR 2B , Glu R3A an d Glu R3 B. European pat entapplicati on,  p ubl ic ation number  EP -A1 -058391 7 discl o ses  t h e hu man sub-unit varia nt G lu R4B.
One  disti n ct iv e  propert yofAMPA a nd ka inic ac id recep tors i s  t he ir rapi ddeacti va tio n a nd de s ensi tizati on to gl utama t e. Yamada andT ang, The Jour n al o fN euro sci ence, Septe mber 1993 , 13 ( 9) : 3 9 04-39 15 an dK at h ryn M. Partin, J. N eu roscie nce,Nov. 1, 1996,  16(21): 6 6 3 4 -6647. T he p h ys i ological impli catio ns of rapi d  desensi tizat ion, and  deactiva t i on if an y,are  no t f u l ly  understood.I t  iskn own tha t t he rapi d d ese nsi tiz at ion and d eactivat io nof  A MPA  and/ o r kainic  a cid  r ece ptors to glu tamat e ma ybe inh ibitedu si n g  cer ta in  com pou nd s. Th is a c tio n of th ese compo und s  isof te n refer red to in the  a lternative  a s “ potent i a tion” of  the receptors. One suc h  compou nd,  whic h se lectively  po tentia tes AMPA r ecepto r fun ct ion , is cy c l ot hia zi de. Partin e t a l., N eu ron.  Vol. 1 1, 1069-1082, 1993 . 
In ternational P ate nt A p p li cat i on Pub li c ati o n  Number WO 9625 926 disclo se s  a  group ofp hen yl thioalk ylsulfo namid e s, S-ox ides andhomologswh icha r e s aid to pot entiatemembranec urren t sinduc edby kai ni c a cid a nd AMP A .
U .S. P at. No .3,143, 549 d is closes c ertain phenylalkylsulfa mides,  incl udi ng 1-meth yl- 2 -ph enylethyl  dim ethylsulfa mid e.The c omp o undsares ai d t o  have  cen t ral nervo u ssys t e mactivity, i n p art icula r a n ti-anx iety  and tranquilizin g  properties.
U .S.P a t.No. 3,26 7, 139 disclosescer ta i n  N′-trim et hylacetyl-N -phenyla lk y sulfa midesand -p henylcy c l op r opylsu lfam ide s having
units GluR5_to GluR7,_and KA-1 and KA-2._Wong and_Mayer,_Molecular Pharmacology_44:_505-510, 1993. It_is not yet_known how these sub-units_are combined in_the_natural state. However, the structures of certain human variants of each sub-unit have been_elucidated,_and cell_lines_expressing_individual sub-unit variants have been_cloned and incorporated into test_systems designed_to identify compounds which bind to or interact_with_them, and hence_which may modulate their function. Thus, European patent application,_publication number EP-A2-0574257 discloses the human_sub-unit variants GluR1B,_GluR2B,_GluR3A_and GluR3B. European patent_application, publication number EP-A1-0583917 discloses the_human sub-unit variant GluR4B.
One distinctive property_of AMPA and kainic acid receptors is_their rapid deactivation and desensitization to_glutamate. Yamada and Tang, The_Journal of_Neuroscience, September 1993, 13(9): 3904-3915_and Kathryn M._Partin, J._Neuroscience, Nov. 1,_1996, 16(21): 6634-6647. The physiological implications_of rapid desensitization,_and deactivation if any, are not_fully_understood.
It is known_that_the_rapid desensitization_and deactivation of_AMPA_and/or kainic_acid_receptors to glutamate may be inhibited_using_certain compounds. This action of these compounds_is often referred to_in_the alternative as “potentiation”_of the receptors. One such_compound, which selectively potentiates AMPA receptor_function, is_cyclothiazide. Partin_et al., Neuron. Vol. 11, 1069-1082, 1993.
International Patent Application Publication Number_WO 9625926 discloses a group of_phenylthioalkylsulfonamides, S-oxides and homologs_which are_said_to potentiate membrane_currents_induced by_kainic acid and AMPA.
U.S. Pat. No. 3,143,549_discloses certain_phenylalkylsulfamides, including 1-methyl-2-phenylethyl dimethylsulfamide. The compounds_are said to have_central_nervous system activity, in particular anti-anxiety_and tranquilizing properties.
U.S. Pat. No. 3,267,139_discloses certain N′-trimethylacetyl-N-phenylalkysulfamides and -phenylcyclopropylsulfamides_having